1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Siremadlin in combination with venetoclax (VEN) plus azacitidine (AZA) in adult patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy: A phase Ib/II trial
    Meeting Abstract

    Daver, N.; Wei, A. H.; Stein, E.; DeAngelo, D. J.; Pathak, D.; Xu, Y.; Grzesiak, S.; Venditti, A.
    Blood (2022)

    Fulltext@MSK | Save
  • Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab
    Meeting Abstract

    Parisi, R.; Cowen, E. A.; Gu, S.; Pulitzer, M.; Geyer, M. B.; King, A. C.; Markova, A.
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1b study of IDH inhibition with enasidenib and MEK inhibition with cobimetinib in patients with relapsed or refractory acute myeloid leukemia who have co-occurring IDH2 and RAS signaling gene mutations
    Meeting Abstract

    Ball, B. J.; Stein, E.; Robbins, M.; Zhang, J.; Levine, R. L.; Synold, T.; Stein, A. S.; Marcucci, G.; Liu, Y.; Danilov, A. V.
    Blood (2022)

    Fulltext@MSK | Save
  • Improvement in individual symptoms and total symptom score (TSS) and matching-adjusted indirect comparison (MAIC) analysis to compare TSS as a continuous endpoint in patients with myelofibrosis treated with pelabresib in combination with ruxolitinib versus janus kinase inhibitor monotherapy
    Meeting Abstract

    Mesa, R.; Kremyanskaya, M.; Patriarca, A.; Gupta, V.; Palandri, F.; Devos, T.; Harrison, C.; Rampal, R. K.; Talpaz, M.; Vannucchi, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Comparison of patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents vs other therapies by TP53 and IDH1/2 mutation: Results from the AML Real World Evidence (ARC) Initiative
    Meeting Abstract

    Wolach, O.; Garcia, J. S.; Desai, P.; Vachhani, P.; Zeidner, J. F.; Abedin, S.; Sweet, K.; Lai, C.; Moshe, Y.; Pollyea, D. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Association of linguistic barriers and survival in allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Walji, M.; Lee, J.; Devlin, S. M.; Gany, F.; Perales, M. A.; Giralt, S. A.; Cho, C.
    Blood (2022)

    Fulltext@MSK | Save
  • Estimating the lifetime medical cost burden of an allogeneic hematopoietic cell transplantation patient and the value of addressing the unmet need
    Meeting Abstract

    Maziarz, R. T.; Devine, S. M.; Garrison, L. P.; Agodoa, I.; Badaracco, J.; Gitlin, M.; Perales, M. A.
    Blood (2022)

    Fulltext@MSK | Save
  • Indirect comparisons of the efficacy of subcutaneous epcoritamab vs chemoimmunotherapy in patients with relapsed or refractory large B-cell lymphoma
    Meeting Abstract

    Salles, G.; Wang, A.; Mutebi, A.; Alshreef, A.; Davies, K. R.; van de Wetering, G.; Chirikov, V.
    Blood (2022)

    Fulltext@MSK | Save
  • Cytokine release syndrome (CRS) is not required for CAR-T cell efficacy in aggressive large B-NHL
    Meeting Abstract

    Bhaskar, S.; Patel, V.; Porter, D. L.; Schuster, S. J.; Nastoupil, L. J.; Perales, M. A.; Tomas, A. A.; Bishop, M. R.; McGuirk, J. P.; Maziarz, R. T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Factors associated with early mortality in patients with multiple myeloma: A SEER analysis
    Meeting Abstract

    Wei, J. X.; Sisto, A.; Shastri, A.; Sica, R. A.; Mantzaris, I.; Kornblum, N.; Shah, U. A.; Janakiram, M.; Gritsman, K.; Verma, A.; more...
    Blood (2022)

    Fulltext@MSK | Save